

Notes from the Field

Tetanus Cases After Voluntary Medical Male Circumcision for HIV Prevention — Eastern and Southern Africa, 2012–2015

Jonathan M. Grund, MA, MPH¹; Carlos Toledo, PhD¹; Stephanie M. Davis, MD¹; Renee Ridzon, MD²; Edna Moturi, MBChB³; Heather Scobie, PhD³; Boubker Naouri, MD³; Jason B. Reed, MD⁴; Emmanuel Njeuhmeli, MD⁵; Anne G. Thomas, PhD⁶; Francis Ndwiga Benson, MSc, MBA⁷; Martin W. Sirengo, MBChB⁷; Leon Ngeruka Muyenzi, MD⁸; Gissege J.I. Lija, MD⁹; John H. Rogers, PhD¹⁰; Salli Mwanasalli, DDS¹⁰; Elijah Odoyo-June, MBChB, PhD¹¹; Nafuna Wamai, MD¹²; Geoffrey Kabuye, MD¹²; James Exnobot Zulu¹³; Jane Ruth Aceng, MBChB¹⁴; Naomi Bock, MD¹

Voluntary medical male circumcision (VMMC) decreases the risk for female-to-male HIV transmission by approximately 60% (1), and the President's Emergency Plan for AIDS Relief (PEPFAR) is supporting the scale-up of VMMC for adolescent and adult males in countries with high prevalence of human immunodeficiency virus (HIV) and low coverage of male circumcision (2). As of September 2015, PEPFAR has supported approximately 8.9 million VMMCs (3).

During April 2012–November 2015, PEPFAR's VMMC program reported 12 tetanus cases in five sub-Saharan African countries. Three cases occurred in 2012–2013 (one in Uganda and two in Zambia), six in 2014 (one each in Kenya, Rwanda, and Tanzania and three in Uganda), and three in 2015 (one in Rwanda and two in Uganda). Eight patients received conventional VMMC surgery, and four received PrePex, a non-surgical male circumcision device. No other VMMC-related tetanus cases had been previously reported. Intensified adverse event and death monitoring and reporting were instituted in July 2014 in all 14 PEPFAR-supported countries providing VMMC for HIV prevention.*

Detailed information was available for eight of the nine cases reported during 2014 and 2015. Based on a case definition established by the World Health Organization (WHO) (4), five of the eight cases were determined by clinical investigation to be causally associated with VMMC. The remaining three were classified as indeterminate because of inconsistent or insufficient data. The age range of patients was 11–47 years. Each patient was deemed eligible for VMMC through preoperative screening and physical examination, and received counseling on postoperative wound care. Among the six causally associated cases in 2014 and 2015, at least three patients (in Kenya,

Tanzania, and Uganda) reportedly had applied traditional remedies to aid healing; these remedies might have contained substances contaminated with spores of *Clostridium tetani*, the causative agent of tetanus.

Six of the nine total cases from 2014 and 2015 were fatal within 12–35 days of circumcision (case fatality ratio = 66.7%). A previous study of tetanus among 154 adolescents and adults at a rural Ugandan hospital reported an in-hospital case fatality ratio of 42.1% among persons aged 14–45 years (5), although this is likely an underestimate because it does not account for deaths following hospital discharge. Several factors, including delays in seeking medical attention, access to tetanus immune globulin, and quality of supportive care, can affect survival.

WHO recommends a 3-dose infant primary series of tetanus vaccination administered as diphtheria-tetanus-pertussis vaccine and, because tetanus immunity wanes over time, 3 booster doses through adolescence and young adulthood (6). However, in most African countries, tetanus vaccination coverage among infants is suboptimal (7), and booster doses required for long-term immunity are predominantly provided for young women as part of maternal and neonatal tetanus elimination programs. As a result, a low proportion of males in the age groups seeking circumcision would be expected to be immune to tetanus.

PEPFAR is working with implementing partners and ministries of health to strengthen national surveillance systems for VMMC-related adverse events, bolster the rapid investigation of reported adverse events, and support the implementation of tetanus mitigation strategies in accordance with WHO tetanus prevention recommendations for VMMC programs, including clean wound care for VMMC clients (4). Despite these 12 reported events, VMMC is safe; <2% of VMMC clients experience moderate or severe adverse events (2). As VMMC scale-up continues, sensitive surveillance systems are needed to monitor all adverse events, including rare events.

Acknowledgments

Catey Laube, Office of the US Global AIDS Coordinator, Washington, DC; Daimon Simbeye, Division of Global HIV and TB (Tanzania), CDC; Stella T. Alamo, Joseph Lubwama, Steven Wiersma, Division of Global HIV and TB (Uganda), CDC; Omega Chituwo, Division of Global HIV and TB (Zambia), CDC.

* Botswana, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, and Zimbabwe.

¹Division of Global HIV and TB, CDC; ²Independent Consultant, Boston, Massachusetts; ³Global Immunization Division, CDC; ⁴Office of the U.S. Global AIDS Coordinator, Washington, DC; ⁵U.S. Agency for International Development, Washington, DC; ⁶Naval Health Research Center, Department of Defense, San Diego, California; ⁷National AIDS and STI Control Programme, Ministry of Health, Nairobi, Kenya; ⁸Rwanda Military Hospital, Ministry of Defence, Kigali, Rwanda; ⁹National AIDS Control Program, Ministry of Health and Social Welfare, Dar es Salaam, Tanzania; ¹⁰Division of Global HIV and TB (Tanzania), CDC; ¹¹Division of Global HIV and TB (Kenya), CDC; ¹²Division of Global HIV and TB (Uganda), CDC; ¹³Ministry of Community Development, Mother and Child Health, Lusaka, Zambia; ¹⁴Uganda Ministry of Health, Kampala, Uganda.

Corresponding author: Jonathan M. Grund, jgrund@cdc.gov, 404-639-8978.

References

1. Siegfried N, Muller M, Deeks JJ, Volmink J. Male circumcision for prevention of heterosexual acquisition of HIV in men. *Cochrane Database Syst Rev* 2009;2:CD003362. <http://dx.doi.org/10.1002/14651858.CD003362>.
2. CDC. Voluntary medical male circumcision—southern and eastern Africa, 2010–2012. *MMWR Morb Mortal Wkly Rep* 2013;62:953–7.
3. US President's Emergency Plan for AIDS Relief. PEPFAR 2015 Latest Results [fact sheet]. Washington, DC: US President's Emergency Plan for AIDS Relief; 2015. <http://www.pepfar.gov/documents/organization/250381.pdf>.
4. World Health Organization. Male circumcision for HIV prevention. Meeting report of the WHO Informal consultation on tetanus and voluntary medical male circumcision, March 9–10, 2015, Geneva, Switzerland. Geneva, Switzerland: World Health Organization; 2015. http://apps.who.int/iris/bitstream/10665/181812/1/9789241509237_eng.pdf.
5. Zziwa GB. Review of tetanus admissions to a rural Ugandan Hospital. *UMU Press* 2009;7:199–202.
6. World Health Organization. Tetanus vaccine.[position paper]. *Wkly Epidemiol Rec* 2006;81:198–208.
7. World Health Organization; United Nations International Children's Emergency Fund. WHO and UNICEF estimates of DTP3 coverage, 2015. Geneva, Switzerland: World Health Organization; 2015. http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveredtp3.html.

REPORT DOCUMENTATION PAGE					<i>Form Approved</i> <i>OMB No. 0704-0188</i>	
The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.						
PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.						
1. REPORT DATE (DD-MM-YYYY) 29-02-2016		2. REPORT TYPE Journal article			3. DATES COVERED (From - To) 4/2012-11/2015	
4. TITLE AND SUBTITLE Tetanus Cases After Voluntary Medical Male Circumcision for HIV Prevention — Eastern and Southern Africa, 2012–2015					5a. CONTRACT NUMBER	
					5b. GRANT NUMBER	
					5c. PROGRAM ELEMENT NUMBER	
					5d. PROJECT NUMBER	
6. AUTHOR(S) Grund, Jonathan M.; Toledo, Carlos; Davis, Stephanie M.; Ridzon, Renee; Moturi, Edna; Scobie, Heather; Naouri, Boubker; Reed, Jason B.; Njeuhmeli, Emmanuel; Thomas, Anne G.; Benson, Francis Ndwiga; Sirengo, Martin W.; Muyenzi, Leon Ngeruka; Lija, Gissenge J.I.; Rogers, John H.; Mwanasalli, Salli; Odoyo-June, Elijah; Wamai, Nafuna; Kabuye, Geoffrey; Zulu, James Exnobot; Aceng, Jane Ruth; Bock, Naomi					5e. TASK NUMBER	
					5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Commanding Officer Naval Health Research Center 140 Sylvester Rd San Diego, CA 92106-3521					8. PERFORMING ORGANIZATION REPORT NUMBER 16-08	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) <div style="display: flex; justify-content: space-between;"> <div> Commanding Officer Naval Medical Research Center 503 Robert Grant Ave Silver Spring, MD 20910-7500 </div> <div> Chief, Bureau of Medicine and Surgery (MED 00), Navy Dept 7700 Arlington Blvd Ste 5113 Falls Church, VA 22042-5113 </div> </div>					10. SPONSOR/MONITOR'S ACRONYM(S) BUMED/NMRC	
					11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release; distribution is unlimited.						
13. SUPPLEMENTARY NOTES Open access publication. MMWR Morb Mortal Wkly Rep, 65(2):36–37, 2016 Jan 22. doi:10.15585/mmwr.mm6502a5						
14. ABSTRACT <p>Voluntary medical male circumcision (VMMC) decreases the risk for female-to-male HIV transmission by approximately 60%, and the President's Emergency Plan for AIDS Relief (PEPFAR) is supporting the scale-up of VMMC for adolescent and adult males in countries with high prevalence of human immunodeficiency virus (HIV) and low coverage of male circumcision. As of September 2015, PEPFAR has supported approximately 8.9 million VMMCs.</p> <p>During April 2012–November 2015, PEPFAR's VMMC program reported 12 tetanus cases in five sub-Saharan African countries. Three cases occurred in 2012–2013 (one in Uganda and two in Zambia), six in 2014 (one each in Kenya, Rwanda, and Tanzania and three in Uganda), and three in 2015 (one in Rwanda and two in Uganda). Eight patients received conventional VMMC surgery, and four received PrePex, a nonsurgical male circumcision device. No other VMMC-related tetanus cases had been previously reported. Intensified adverse event and death monitoring and reporting were instituted in July 2014 in all 14 PEPFAR-supported countries providing VMMC for HIV prevention.</p>						
15. SUBJECT TERMS HIV, AIDS, tetanus, voluntary medical male circumcision						
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 2	19a. NAME OF RESPONSIBLE PERSON Commanding Officer	
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (Include area code) COMM/DSN: (619) 553-8429	